Published in Science on October 23, 1987
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A (1995) 1.91
Passive case-finding for Alzheimer's disease and dementia in two U.S. communities. Alzheimers Dement (2011) 1.05
Hypothesis: microtubules, a key to Alzheimer disease. Proc Natl Acad Sci U S A (1989) 0.88
Stimulated platelets release amyloid beta-protein precursor. Biochem Biophys Res Commun (1990) 0.83
Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl) (2007) 0.78
Age-related changes in peripheral benzodiazepine receptors of human platelets. J Psychiatry Neurosci (1994) 0.77
An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiatr Dis Treat (2008) 0.76
Changes in peripheral benzodiazepine receptors in patients with bipolar disorder. Neuropsychiatr Dis Treat (2005) 0.75
Factors Determining Conjugation in Paramecium Aurelia II. Genetic Diversities between Stocks or Races. Genetics (1936) 3.54
Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry (1989) 2.07
Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry (1989) 1.94
Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology (2004) 1.87
Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol (1980) 1.78
Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (1998) 1.75
Familial idiopathic cerebral calcifications. J Neurol Neurosurg Psychiatry (1977) 1.75
Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex (1987) 1.68
Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry (2000) 1.66
Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry (1988) 1.64
Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol (1994) 1.51
EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology (1997) 1.48
Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol (1999) 1.45
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med (2010) 1.43
Severe adverse interaction between pethidine and selegiline. Lancet (1991) 1.42
Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. Arch Neurol (1984) 1.41
Preliminary Observations on the Epidemiology of Mental Disease. Am J Public Health Nations Health (1939) 1.40
[Difficulties in differential diagnosis of long-term Creutzfeldt- Jakob disease]. Neurologia (1995) 1.39
Severe daytime somnolence in patients treated with an MAOI. Am J Psychiatry (1988) 1.38
Centralized Collection of Marriage and Divorce Records and Their Uses. Am J Public Health Nations Health (1941) 1.37
The alien hand syndrome. Clinical and postmortem findings. Arch Neurol (1989) 1.35
Survival following first diagnosis of coronary heart disease. Am Heart J (1969) 1.35
Age-related reduction in functional MRI response to photic stimulation. Neurology (1997) 1.34
Reduction in BOLD fMRI response to primary visual stimulation following alcohol ingestion. Psychiatry Res (1998) 1.32
Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci U S A (1992) 1.30
Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology (1993) 1.30
Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry (1996) 1.29
Influence of baseline hematocrit and hemodilution on BOLD fMRI activation. Magn Reson Imaging (2001) 1.29
The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry (2000) 1.28
Functional magnetic resonance imaging of facial affect recognition in children and adolescents. J Am Acad Child Adolesc Psychiatry (1999) 1.27
Prazosin hydrochloride (CP-12,299-1), an oral anti-hypertensive agent: preliminary clinical observations in ambulatory patients. J Clin Pharmacol J New Drugs (1970) 1.27
Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA (1998) 1.23
Cocaine pharmacokinetics in men and in women during the follicular and luteal phases of the menstrual cycle. Neuropsychopharmacology (1999) 1.22
Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol (1997) 1.20
Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. Bipolar Disord (2000) 1.18
The natural history of Alzheimer's disease. Description of study cohort and accuracy of diagnosis. Arch Neurol (1994) 1.17
Amygdala atrophy in Alzheimer's disease. An in vivo magnetic resonance imaging study. Arch Neurol (1993) 1.15
The validity of DSM-III borderline personality disorder. A phenomenologic, family history, treatment response, and long-term follow-up study. Arch Gen Psychiatry (1983) 1.13
Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry (2001) 1.10
Antidepressant-related akathisia. J Clin Psychopharmacol (1987) 1.09
Neuropsychological function in Alzheimer's disease. Pattern of impairment and rates of progression. Arch Neurol (1988) 1.09
Simple reaction time: evidence for focal impairment from lesions of the right hemisphere. Brain (1975) 1.08
"Schizoaffective disorder": an invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder. Am J Psychiatry (1980) 1.08
Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry (2000) 1.08
Maurice Ravel and right-hemisphere musical creativity: influence of disease on his last musical works? Eur J Neurol (2002) 1.04
MRI description of cerebral atrophy in mouse lemur primates. Neurobiol Aging (2000) 1.04
Spino-pontine degeneration. Eur Neurol (1969) 1.03
Computerized EEG spectral analysis in elderly normal, demented and depressed subjects. Electroencephalogr Clin Neurophysiol (1986) 1.03
Anosognosia, intrusions and 'frontal' functions in Alzheimer's disease and depression. Neuropsychologia (1995) 1.01
Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand (2005) 1.01
Acute aromatics inhalation modifies the airways. Effects of the common cold. Respiration (1982) 1.00
Familial palilalia. Neurology (1973) 1.00
Latent sensory aphasia in hemisphere-damaged patients: an experimental study with the Token Test. Brain (1966) 0.99
Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry (1997) 0.99
Cognitive deficits and clinical diagnosis of Alzheimer's disease. Neurology (1987) 0.98
Discrimination of facial identity and of emotions in Alzheimer's disease. J Neurol Sci (1998) 0.97
Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl Psychiatry (2013) 0.97
Differences in cerebellar blood volume in schizophrenia and bipolar disorder. Schizophr Res (1999) 0.96
Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry (1994) 0.96
Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl (1992) 0.96
Association of the apolipoprotein E epsilon4 allele with late-onset depression. Neuroepidemiology (2001) 0.95
Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology (1995) 0.94
Dynorphinergic GABA neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus. Neuroscience (2003) 0.94
Cerebral T2-weighted signal decrease during aging in the mouse lemur primate reflects iron accumulation. Neurobiol Aging (1998) 0.94
Learning deficit in Parkinson's disease. Comparison with Alzheimer's disease and normal aging. Arch Neurol (1987) 0.94
Computed tomography--but not magnetic resonance imaging--identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol (1995) 0.94
Sequential dynamic susceptibility contrast MR experiments in human brain: residual contrast agent effect, steady state, and hemodynamic perturbation. Magn Reson Med (1995) 0.93
Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch Neurol (1988) 0.92
Thalamic and subcortical gliosis with dementia. Arch Neurol (1987) 0.92
The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand (1990) 0.92
Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl) (2002) 0.91
Risk of dementia in relatives of patients with Alzheimer's disease. Neurology (1988) 0.91
Abnormal cerebral metabolism in polydrug abusers during early withdrawal: a 31P MR spectroscopy study. Magn Reson Med (1996) 0.90
Persistent reduction of immediate early gene mRNA in rat forebrain following single or multiple doses of cocaine. Brain Res Mol Brain Res (1994) 0.90
Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry (2000) 0.90
Neuropsychiatric correlates of cerebral white-matter radiolucencies in probable Alzheimer's disease. Arch Neurol (1992) 0.90
Palilalia. Br J Disord Commun (1975) 0.89
Biexponential transverse relaxation (T(2)) of the proton MRS creatine resonance in human brain. Magn Reson Med (2002) 0.89
Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry (1984) 0.89
Airways flow resistance as a measure of the efficacy of inhalants in clinical drug trials. Helv Med Acta (1969) 0.88
Failure to find evidence of schizophrenia in first-degree relatives of schizophrenic probands. Am J Psychiatry (1982) 0.88
Cocaine decreases relative cerebral blood volume in humans: a dynamic susceptibility contrast magnetic resonance imaging study. Psychopharmacology (Berl) (1998) 0.87
Acalculia: historical development and current significance. Brain Cogn (1983) 0.87
In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci (1986) 0.87
The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol (2000) 0.86
Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. Eur J Neurol (1999) 0.86
Tolerance to therapeutic effects of antidepressants. Am J Psychiatry (1985) 0.86
Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. Am J Med Genet (1994) 0.86
T2-weighted MRI studies of mouse lemurs: a primate model of brain aging. Neurobiol Aging (1997) 0.86
Assessment of GABA concentration in human brain using two-dimensional proton magnetic resonance spectroscopy. Psychiatry Res (2000) 0.86
Cocaine-induced cerebral vasoconstriction differs as a function of sex and menstrual cycle phase. Biol Psychiatry (2001) 0.86
A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radiofrequency pulses. Magn Reson Med (1996) 0.86
Use of semantic context by patients with Alzheimer's disease. Psychol Aging (1986) 0.86
The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry (1992) 0.86
Remote memory in Alzheimer's disease. J Neuropsychiatry Clin Neurosci (1999) 0.85
Delayed auditory feedback and aphasia. Cortex (1978) 0.85
Optic ataxia: clinical-radiological correlations with the EMIscan. J Neurol Neurosurg Psychiatry (1975) 0.85
Explicit memory, procedural learning and lexical priming in Alzheimer's disease. Cortex (1994) 0.85
Specificity of temporal amygdala atrophy in Alzheimer's disease: quantitative assessment with magnetic resonance imaging. Dementia (1996) 0.85
Paroxysmal "nightmares". Sequel of a stroke responsive to diphenylhydantoin. Neurology (1975) 0.85